Comparative Effectiveness and Safety of LAMA-LABA Inhalers in Chronic Obstructive Pulmonary Disease - PubMed
4 hours ago
- #COPD
- #LAMA-LABA
- #bronchodilator
- Dual bronchodilator therapy with LAMA-LABA is recommended for symptomatic COPD patients.
- The study compared effectiveness and safety of three LAMA-LABA inhalers: umeclidinium-vilanterol (dry powder), glycopyrrolate-formoterol (metered-dose), and tiotropium-olodaterol (soft mist).
- Umeclidinium-vilanterol showed a 14% lower hazard of COPD exacerbation compared to glycopyrrolate-formoterol and a 3% lower hazard compared to tiotropium-olodaterol.
- Tiotropium-olodaterol had a 6% lower hazard of COPD exacerbation than glycopyrrolate-formoterol.
- No significant differences were found in risks of major adverse cardiovascular events, urinary tract infections, or pneumonia hospitalizations among the three inhalers.
- Umeclidinium-vilanterol dry powder inhalers may be preferred for new LAMA-LABA therapy users due to better clinical outcomes.